Is OCUL or OCS more profitable?

Ocular Therapeutix has a net margin of -579.10% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Ocular Therapeutix's return on equity. Company Net Margins Return on Equity Return on Assets Ocular Therapeutix -579.10% -59.89% -45.99% Oculis -6,777.18% -42.61% -35.23%

Does the media favor OCUL or OCS?

In the previous week, Oculis had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 7 mentions for Oculis and 6 mentions for Ocular Therapeutix. Oculis' average media sentiment score of 0.67 beat Ocular Therapeutix's score of 0.33 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, OCS or TRLV?

Trulieve Cannabis has lower revenue, but higher earnings than Oculis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 399.46 -$119.44M -$1.74 N/A Trulieve Cannabis N/A N/A N/A N/A N/A

Does the media favor OCS or TRLV?

In the previous week, Oculis had 3 more articles in the media than Trulieve Cannabis. MarketBeat recorded 7 mentions for Oculis and 4 mentions for Trulieve Cannabis. Oculis' average media sentiment score of 0.67 beat Trulieve Cannabis' score of 0.20 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OCS or PBH?

In the previous week, Oculis had 5 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 7 mentions for Oculis and 2 mentions for Prestige Consumer Healthcare. Oculis' average media sentiment score of 0.67 beat Prestige Consumer Healthcare's score of 0.23 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prestige Consumer Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TRVI or OCS more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Oculis -6,777.18% -42.61% -35.23%

Does the media favor TRVI or OCS?

In the previous week, Oculis had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 7 mentions for Oculis and 5 mentions for Trevi Therapeutics. Oculis' average media sentiment score of 0.67 beat Trevi Therapeutics' score of 0.65 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, BHC or OCS?

Bausch Health Cos has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Cos $10.27B 0.21 $157M -$2.96 N/A Oculis $1.45M 399.46 -$119.44M -$1.74 N/A

Is BHC or OCS more profitable?

Bausch Health Cos has a net margin of -10.12% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -10.12% -561.95% 6.31% Oculis -6,777.18% -42.61% -35.23%

Does the media favor BHC or OCS?

In the previous week, Bausch Health Cos and Bausch Health Cos both had 7 articles in the media. Bausch Health Cos' average media sentiment score of 1.17 beat Oculis' score of 0.67 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oculis (OCS) Competitors

$9.99 -0.72 (-6.72%)

Closing price 04:00 PM Eastern

Extended Trading

$10.15 +0.16 (+1.64%)

As of 07:30 PM Eastern

Compare

OCS vs. OCUL, TRLV, PBH, TRVI, and BHC

Should you buy Oculis stock or one of its competitors? Oculis's main competitors and comparable companies include Ocular Therapeutix (OCUL), Trulieve Cannabis (TRLV), Prestige Consumer Healthcare (PBH), Trevi Therapeutics (TRVI), and Bausch Health Cos (BHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Oculis compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

In the previous week, Oculis had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 7 mentions for Oculis and 6 mentions for Ocular Therapeutix. Oculis' average media sentiment score of 0.67 beat Ocular Therapeutix's score of 0.33 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has a net margin of -579.10% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Oculis	-6,777.18%	-42.61%	-35.23%

Ocular Therapeutix currently has a consensus target price of $25.75, suggesting a potential upside of 157.50%. Oculis has a consensus target price of $39.44, suggesting a potential upside of 294.84%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ocular Therapeutix has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Oculis has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Oculis has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$52.06M	42.19	-$265.94M	-$1.42	N/A
Oculis	$1.45M	399.46	-$119.44M	-$1.74	N/A

Summary

Oculis beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

How does Oculis compare to Trulieve Cannabis?

Oculis (NASDAQ:OCS) and Trulieve Cannabis (NYSE:TRLV) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

22.3% of Oculis shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Trulieve Cannabis has lower revenue, but higher earnings than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	399.46	-$119.44M	-$1.74	N/A
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

In the previous week, Oculis had 3 more articles in the media than Trulieve Cannabis. MarketBeat recorded 7 mentions for Oculis and 4 mentions for Trulieve Cannabis. Oculis' average media sentiment score of 0.67 beat Trulieve Cannabis' score of 0.20 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oculis currently has a consensus price target of $39.44, indicating a potential upside of 294.84%. Trulieve Cannabis has a consensus price target of $15.00, indicating a potential upside of 19.81%. Given Oculis' stronger consensus rating and higher possible upside, equities analysts clearly believe Oculis is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Trulieve Cannabis has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trulieve Cannabis' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Trulieve Cannabis	N/A	N/A	N/A

Summary

Oculis beats Trulieve Cannabis on 7 of the 11 factors compared between the two stocks.

How does Oculis compare to Prestige Consumer Healthcare?

Oculis (NASDAQ:OCS) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Oculis had 5 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 7 mentions for Oculis and 2 mentions for Prestige Consumer Healthcare. Oculis' average media sentiment score of 0.67 beat Prestige Consumer Healthcare's score of 0.23 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.3% of Oculis shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Oculis' net margin of -6,777.18%. Prestige Consumer Healthcare's return on equity of 11.39% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Prestige Consumer Healthcare has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	399.46	-$119.44M	-$1.74	N/A
Prestige Consumer Healthcare	$1.09B	2.00	$190.30M	$3.57	12.88

Oculis currently has a consensus price target of $39.44, indicating a potential upside of 294.84%. Prestige Consumer Healthcare has a consensus price target of $70.75, indicating a potential upside of 53.82%. Given Oculis' stronger consensus rating and higher probable upside, research analysts clearly believe Oculis is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Oculis has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Summary

Prestige Consumer Healthcare beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Oculis compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Trevi Therapeutics has higher earnings, but lower revenue than Oculis. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Oculis	$1.45M	399.46	-$119.44M	-$1.74	N/A

Trevi Therapeutics currently has a consensus price target of $27.08, indicating a potential upside of 87.30%. Oculis has a consensus price target of $39.44, indicating a potential upside of 294.84%. Given Oculis' higher probable upside, analysts plainly believe Oculis is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Trevi Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Oculis has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

In the previous week, Oculis had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 7 mentions for Oculis and 5 mentions for Trevi Therapeutics. Oculis' average media sentiment score of 0.67 beat Trevi Therapeutics' score of 0.65 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Trevi Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Trevi Therapeutics' return on equity of -23.59% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Oculis	-6,777.18%	-42.61%	-35.23%

Summary

Trevi Therapeutics beats Oculis on 11 of the 16 factors compared between the two stocks.

How does Oculis compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Oculis (NASDAQ:OCS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bausch Health Cos has a net margin of -10.12% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Oculis	-6,777.18%	-42.61%	-35.23%

Bausch Health Cos has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Oculis has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Bausch Health Cos presently has a consensus price target of $8.00, suggesting a potential upside of 40.08%. Oculis has a consensus price target of $39.44, suggesting a potential upside of 294.84%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Bausch Health Cos has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A
Oculis	$1.45M	399.46	-$119.44M	-$1.74	N/A

In the previous week, Bausch Health Cos and Bausch Health Cos both had 7 articles in the media. Bausch Health Cos' average media sentiment score of 1.17 beat Oculis' score of 0.67 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bausch Health Cos beats Oculis on 9 of the 16 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCS vs. The Competition

Export

Metric	Oculis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$579.22M	$12.42B	$7.21B	$13.10B
Dividend Yield	N/A	2.63%	2.53%	13.00%
P/E Ratio	-5.74	794.80	274.58	25.69
Price / Sales	399.46	830.70	648.78	85.88
Price / Cash	N/A	86.22	76.31	52.02
Price / Book	2.45	10.62	10.44	6.32
Net Income	-$119.44M	$2.81B	$3.49B	$359.73M
7 Day Performance	0.81%	0.73%	0.51%	1.35%
1 Month Performance	-23.68%	-1.67%	-3.38%	-3.68%
1 Year Performance	-43.72%	3.07%	16.04%	5.56%

Oculis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCS Oculis	2.5386 of 5 stars	$9.99 -6.7%	$39.44 +294.8%	-39.6%	$579.22M	$1.45M	N/A	60
OCUL Ocular Therapeutix	3.0072 of 5 stars	$10.20 -4.9%	$25.75 +152.6%	-13.9%	$2.25B	$51.95M	N/A	325	Positive News
TRLV Trulieve Cannabis	2.9467 of 5 stars	$11.46 -1.4%	$15.00 +30.9%	N/A	$2.21B	N/A	N/A	5,000
PBH Prestige Consumer Healthcare	2.9129 of 5 stars	$46.49 -2.4%	$70.75 +52.2%	-25.0%	$2.21B	$1.09B	13.04	890	Positive News
TRVI Trevi Therapeutics	3.7569 of 5 stars	$15.06 -5.2%	$27.08 +79.8%	+78.2%	$2.15B	N/A	N/A	34

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCS) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oculis (OCS) Competitors

OCS vs. OCUL, TRLV, PBH, TRVI, and BHC

How does Oculis compare to Ocular Therapeutix?

Summary

How does Oculis compare to Trulieve Cannabis?

Summary

How does Oculis compare to Prestige Consumer Healthcare?

Summary

How does Oculis compare to Trevi Therapeutics?

Summary

How does Oculis compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oculis (OCS) Competitors

OCS vs. OCUL, TRLV, PBH, TRVI, and BHC

How does Oculis compare to Ocular Therapeutix?

Does the media favor OCUL or OCS?

Is OCUL or OCS more profitable?

Do analysts prefer OCUL or OCS?

Do insiders and institutionals believe in OCUL or OCS?

Which has more risk and volatility, OCUL or OCS?

Which has stronger earnings & valuation, OCUL or OCS?

Summary

How does Oculis compare to Trulieve Cannabis?

Do insiders and institutionals have more ownership in OCS or TRLV?

Which has preferable valuation & earnings, OCS or TRLV?

Does the media favor OCS or TRLV?

Do analysts rate OCS or TRLV?

Is OCS or TRLV more profitable?

Summary

How does Oculis compare to Prestige Consumer Healthcare?

Does the media refer more to OCS or PBH?

Do institutionals and insiders have more ownership in OCS or PBH?

Is OCS or PBH more profitable?

Which has better valuation and earnings, OCS or PBH?

Do analysts rate OCS or PBH?

Which has more risk & volatility, OCS or PBH?

Summary

How does Oculis compare to Trevi Therapeutics?

Which has better valuation and earnings, TRVI or OCS?

Do analysts rate TRVI or OCS?

Which has more volatility & risk, TRVI or OCS?

Does the media favor TRVI or OCS?

Do institutionals & insiders have more ownership in TRVI or OCS?

Is TRVI or OCS more profitable?

Summary

How does Oculis compare to Bausch Health Cos?

Do institutionals & insiders hold more shares of BHC or OCS?

Is BHC or OCS more profitable?

Which has more volatility and risk, BHC or OCS?

Do analysts prefer BHC or OCS?

Which has preferable earnings and valuation, BHC or OCS?

Does the media favor BHC or OCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools